| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Ariel L Barka. Biochemical markers of acromegaly: GH vs. IGF-I. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 14 Suppl A. 2005-10-18. PMID:15135787. |
this review briefly discusses the performance parameters of gh and igf-i as diagnostic and surveillance tools in patients with acromegaly. |
2005-10-18 |
2023-08-12 |
Not clear |
| Angela N Paisley, Peter J Trainer, William M Drak. The place of pegvisomant in the acromegaly treatment algorithm. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 14 Suppl A. 2005-10-18. PMID:15135788. |
the disfiguring disease acromegaly results from hypersecretion of growth hormone (gh). |
2005-10-18 |
2023-08-12 |
Not clear |
| Laurence Katznelso. Diagnosis and treatment of acromegaly. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 15 Suppl A. 2005-10-18. PMID:16023876. |
acromegaly is an insidious disease that occurs, in the majority of cases, as a result of a pituitary adenoma that hypersecretes growth hormone (gh). |
2005-10-18 |
2023-08-12 |
Not clear |
| Laurence Katznelso. Diagnosis and treatment of acromegaly. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 15 Suppl A. 2005-10-18. PMID:16023876. |
the clinical consequences of acromegaly are a function of excess gh secretion and mass effect of the pituitary tumor. |
2005-10-18 |
2023-08-12 |
Not clear |
| Nienke R Biermasz, Alberto M Pereira, Jan W A Smit, Johannes A Romijn, Ferdinand Roelfsem. Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 15. issue 3. 2005-10-11. PMID:15935982. |
therefore, we assessed the acute responses of serum gh levels to a new octreotide test (intravenous administration of 50 microg) in 98 consecutive patients with active acromegaly and we measured the predictive value of this test for the efficacy of chronic octreotide-long acting repeatable (octreotide-lar) treatment in 18 patients. |
2005-10-11 |
2023-08-12 |
Not clear |
| S Yarman, O Minarec. Value of petrosal sinus sampling: coexisting acromegaly, empty sella and meningioma. Neuroradiology. vol 46. issue 12. 2005-09-27. PMID:15580492. |
simultaneous occurrence of an intracranial meningioma and a growth hormone (gh)-producing pituitary adenoma is exceedingly rare, as is coexistence of an empty sella and acromegaly. |
2005-09-27 |
2023-08-12 |
Not clear |
| Kazunori Kageyama, Takako Moriyama, Satoru Sakihara, Shinobu Takayasu, Takeshi Nigawara, Toshihiro Sud. Usefulness of the thyrotropin-releasing hormone test in pre-clinical acromegaly. The Tohoku journal of experimental medicine. vol 206. issue 4. 2005-09-27. PMID:15997199. |
acromegaly is caused primarily by pituitary growth hormone (gh)-secreting tumors. |
2005-09-27 |
2023-08-12 |
Not clear |
| A Bhansali, P Velayutham, R Sialy, B Seth. Effect of opiates on growth hormone secretion in acromegaly. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. vol 37. issue 7. 2005-09-27. PMID:16034714. |
morphine at doses of 5 mg and 10 mg does not stimulate growth hormone (gh) secretion in normal subjects, and its effect on gh secretion in acromegaly is not widely documented. |
2005-09-27 |
2023-08-12 |
human |
| A Bhansali, P Velayutham, R Sialy, B Seth. Effect of opiates on growth hormone secretion in acromegaly. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. vol 37. issue 7. 2005-09-27. PMID:16034714. |
we conclude that higher doses (15 mg) of morphine are required to stimulate gh secretion in normal subjects, and that opioids exert a positive modulating effect on growth hormone secretion in patients with active acromegaly suggesting partial autonomy of the pituitary tumor. |
2005-09-27 |
2023-08-12 |
human |
| Cheryl A Picket. Update on the medical management of pituitary adenomas. Current neurology and neuroscience reports. vol 5. issue 3. 2005-09-23. PMID:15865883. |
the introduction of a gh receptor antagonist in the 1990s has added to the pharmacologic armamentarium for treatment of acromegaly. |
2005-09-23 |
2023-08-12 |
Not clear |
| M Rix, P Laurberg, A S Hoejberg, B Brock-Jacobse. Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl. European journal of endocrinology. vol 153. issue 2. 2005-09-21. PMID:16061823. |
the use of a growth hormone (gh) receptor antagonist, pegvisomant has shown great promise in adults with acromegaly, but experience in paediatric patients is lacking. |
2005-09-21 |
2023-08-12 |
Not clear |
| W M Drake, D M Berney, K Kovacs, J P Monso. Markers of cell proliferation in a GH-producing adenoma of a patient treated with pegvisomant. European journal of endocrinology. vol 153. issue 2. 2005-09-21. PMID:16061824. |
we report our findings on markers of cell proliferation (ki-67 labelling index and topoisomerase-alpha expression) in a somatotroph pituitary tumour before and after exposure to pegvisomant, a gh receptor antagonist developed for the treatment of acromegaly. |
2005-09-21 |
2023-08-12 |
Not clear |
| Hiroshi Nishioka, Jo Haraoka, Tamotsu Mik. Spontaneous remission of functioning pituitary adenomas without hypopituitarism following infarctive apoplexy: two case reports. Endocrine journal. vol 52. issue 1. 2005-09-13. PMID:15758567. |
the findings were consistent with the presence of selective infarct of a gh adenoma and a prolactinoma that had led to remission of acromegaly and menstrual disturbance, respectively, without pituitary insufficiency. |
2005-09-13 |
2023-08-12 |
Not clear |
| U Plöckinger, H-J Quabb. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study. Acta neurochirurgica. vol 147. issue 5. 2005-08-18. PMID:15806331. |
presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (gh) concentration and pituitary function. |
2005-08-18 |
2023-08-12 |
Not clear |
| U Plöckinger, H-J Quabb. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study. Acta neurochirurgica. vol 147. issue 5. 2005-08-18. PMID:15806331. |
we evaluated in an acromegaly case-control study the effect of octreotide pre-treatment on short- and long-term postoperative gh concentrations, pituitary function and glucose tolerance. |
2005-08-18 |
2023-08-12 |
Not clear |
| Peiming Ma, Yanfeng Wang, Joost van der Hoek, Jerry Nedelman, Horst Schran, Ly-Le Tran, Steven W J Lambert. Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly. Clinical pharmacology and therapeutics. vol 78. issue 1. 2005-08-18. PMID:16003295. |
acromegaly is a serious hormonal disorder resulting from a pituitary adenoma causing excess growth hormone (gh) production. |
2005-08-18 |
2023-08-12 |
Not clear |
| J Svensson, A Tivesten, J Isgaar. Growth hormone and the cardiovascular function. Minerva endocrinologica. vol 30. issue 1. 2005-08-17. PMID:15877009. |
physiological effects of gh are discussed as well as the cardiac dysfunction caused both by gh excess (acromegaly) and by gh deficiency in adult hypopituitary patients. |
2005-08-17 |
2023-08-12 |
Not clear |
| J Svensson, A Tivesten, J Isgaar. Growth hormone and the cardiovascular function. Minerva endocrinologica. vol 30. issue 1. 2005-08-17. PMID:15877009. |
in both acromegaly and adult gh deficiency, there is also increased cardiovascular morbidity and mortality. |
2005-08-17 |
2023-08-12 |
Not clear |
| Ritva Kauppinen-Mäkelin, Timo Sane, Antti Reunanen, Matti J Välimäki, Leo Niskanen, Helene Markkanen, Eliisa Löyttyniemi, Tapani Ebeling, Pia Jaatinen, Hanna Laine, Pirjo Nuutila, Pasi Salmela, Jorma Salmi, Ulf-Håkan Stenman, Jorma Viikari, Erkki Voutilaine. A nationwide survey of mortality in acromegaly. The Journal of clinical endocrinology and metabolism. vol 90. issue 7. 2005-08-09. PMID:15886256. |
increased mortality in acromegaly has been confined to those with posttreatment basal gh of 2.5 microg/liter or greater, but the impact of igf-i and pituitary radiotherapy on mortality has remained controversial. |
2005-08-09 |
2023-08-12 |
Not clear |
| William M Drake, Peter J Traine. Clinical use of pegvisomant for the treatment of acromegaly. Treatments in endocrinology. vol 2. issue 6. 2005-07-12. PMID:15981941. |
studies have shown that the drug is able to normalize circulating levels of insulin-like growth factor-1 (igf-1), the principal mediator of gh action, in 97% of patients with active acromegaly, as well as improve the symptoms and signs associated with gh excess. |
2005-07-12 |
2023-08-12 |
Not clear |